NasdaqGM - Nasdaq Real Time Price USD
Altimmune, Inc. (ALT)
As of 1:14 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
52.00
426.00
-68.00
4,410.00
8,185.03
Operating Expense
99,562.00
83,936.00
87,672.00
89,954.00
62,983.77
Operating Income
-99,510.00
-83,510.00
-87,740.00
-85,544.00
-54,798.74
Net Non Operating Interest Income Expense
8,459.00
7,316.00
2,862.00
198.00
313.09
Other Income Expense
-12,469.00
-12,253.00
-32.00
-11,744.00
24.15
Pretax Income
-103,520.00
-88,447.00
-84,910.00
-97,090.00
-54,461.50
Tax Provision
--
--
-197.00
--
-5,417.02
Net Income Common Stockholders
-103,520.00
-88,447.00
-84,713.00
-97,090.00
-49,044.48
Diluted NI Available to Com Stockholders
-103,520.00
-88,447.00
-84,713.00
-97,090.00
-49,044.48
Basic EPS
-1.57
-1.66
-1.81
-2.35
-1.91
Diluted EPS
-1.57
-1.66
-1.81
-2.35
-1.91
Basic Average Shares
67,820.39
53,246.94
46,926.35
41,283.50
25,637.02
Diluted Average Shares
67,820.39
53,246.94
46,926.35
41,283.50
25,637.02
Total Operating Income as Reported
-111,929.00
-95,929.00
-87,740.00
-96,914.00
-54,798.74
Total Expenses
99,562.00
83,936.00
87,672.00
89,954.00
62,983.77
Net Income from Continuing & Discontinued Operation
-103,520.00
-88,447.00
-84,713.00
-97,090.00
-49,044.48
Normalized Income
-91,101.00
-76,028.00
-84,713.00
-85,720.00
-49,044.48
Interest Income
8,469.00
7,351.00
2,870.00
203.00
322.51
Interest Expense
10.00
35.00
8.00
5.00
9.42
Net Interest Income
8,459.00
7,316.00
2,862.00
198.00
313.09
EBIT
-103,510.00
-88,412.00
-84,902.00
-97,085.00
-54,452.08
EBITDA
-103,191.00
-87,935.00
-84,409.00
-96,534.00
-54,023.20
Reconciled Depreciation
319.00
477.00
493.00
551.00
428.88
Net Income from Continuing Operation Net Minority Interest
-103,520.00
-88,447.00
-84,713.00
-97,090.00
-49,044.48
Total Unusual Items Excluding Goodwill
-12,419.00
-12,419.00
--
-11,370.00
--
Total Unusual Items
-12,419.00
-12,419.00
--
-11,370.00
--
Normalized EBITDA
-90,772.00
-75,516.00
-84,409.00
-85,164.00
-54,023.20
Tax Rate for Calcs
--
--
0.00
--
0.00
12/31/2020 - 5/26/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VKTX Viking Therapeutics, Inc.
53.82
+4.44%
MDGL Madrigal Pharmaceuticals, Inc.
325.54
+2.66%
IOVA Iovance Biotherapeutics, Inc.
8.33
+2.33%
TERN Terns Pharmaceuticals, Inc.
5.75
+2.75%
TGTX TG Therapeutics, Inc.
34.91
+12.07%
IBRX ImmunityBio, Inc.
5.09
+4.31%
SAVA Cassava Sciences, Inc.
29.84
+14.55%
GPCR Structure Therapeutics Inc.
31.33
-4.22%
NTLA Intellia Therapeutics, Inc.
14.35
+9.38%
SMMT Summit Therapeutics Inc.
18.96
+1.83%